Liraglutide: A human GLP-1 analogue for the treatment of type 2 diabetes

Formulary

Volumn 44, Issue 5, 2009, Pages 136-142

  Sakauye, Stacie D ^a   Shah, Sachin A ^a  

^a UNIVERSITY OF THE PACIFIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; DIGOXIN; EXENDIN 4; GLIMEPIRIDE; GRISEOFULVIN; HEMOGLOBIN A1C; INSULIN GLARGINE; LIRAGLUTIDE; LISINOPRIL; METFORMIN; PLACEBO; ROSIGLITAZONE; SULFONYLUREA;

CHRONIC PANCREATITIS; COMBINATION CHEMOTHERAPY; DIARRHEA; DIZZINESS; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG USE; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPOGLYCEMIA; INJECTION SITE CONTUSION; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW; TREATMENT DURATION; VOMITING;

EID: 77951970320     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Diabetes statistics. American Diabetes Association website. http://www.diabetes.org/diabetes-statistics.jsp. Accessed April 13, 2009.
2. Resnick HE, Foster GL, Bardsley J, Ratner RE. Achievement of American Diabetes Association clinical practice recommendations among US adults with diabetes, 1999-2002: The National Health and Nutrition Examination Survey. Diabetes Care. 2006;29:531-537.
3. Van Gaal LF, Gutkin SW, Nauck MA. Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: Glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control? Eur J Endocrinol. 2008;158:773-784.
4. Srinivasan BT, Jarvis J, Khunti K, Davies MJ. Recent advances in the management of type 2 diabetes mellitus: A review. Postgrad Med J. 2008;84:524-531.
5. Bray GM. Exenatide. Am J Health Syst Pharm. 2006;63:411-418.
6. Green J, Feinglos M. New combination treatment in the management of diabetes: focus on sitagliptin-metformin. Vasc Health Risk Manag. 2008;4:743-751.
7. Update on FDA advisory committee meeting on liraglutide for the treatment of type 2 diabetes (2 April 2009) [press release]. Princeton, NJ: Novo Nordisk; April 2, 2009.
8. Drucker DJ, Nauck MA. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696-1705.
9. Russell-Jones D. Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue. Mol Cell Endocrinol. 2009;297:137-140.
10. Marre M, Shaw J, Brandle M et al; LEAD-1 SU study group. Liraglutide, a once daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med. 2009;26:268-278.
11. Nauck M, Frid A, Hermansen K, et al; LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo all in combination with metformin, in type 2 diabetes: The LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32:84-90.
12. Elbrond B, Jakobsen G, Larsen S, et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care. 2002;25:1398-1404.
13. Kapitza C, Flint A, Spitzer H, Hindsberger C, Zdravkovic M. The effect of three different injection sites on the pharmacokinetics of the once-daily human GLP-1 analogue liraglutide [abstract]. Presented at: The American Diabetes Association's 68th Scientific Sessions; June 6-10, 2008; San Francisco, CA. Abstract 2146-PO.
14. Jonker DM, Watson E, Toft AD, Kristensen P, Knudsen LB, Ingwersen SH. Pharmacokinetic modelling of the once-daily human glucagon-like peptide-1 analogue, liraglutide, in healthy volunteers and comparison to exenatide [abstract]. Diabetologia. 2007;50(suppl 1):S351-S352. Abstract 0850.
15. Steensgaard DB, Thomsen JK, Olsen HB, Knudsen LB. The molecular basis for the delayed absorption of the once-daily human GLP-1 analog, liraglutide [abstract]. Presented at: The American Diabetes Association's 68th Scientific Sessions; June 6-10, 2008; San Francisco, CA. Abstract 552-P.
16. Agerso H, Jensen LB, Elbrond B, Rolan P, Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia. 2002;45:195-202.
17. 3H]-liraglutide in human healthy subjects [abstract]. Presented at: The American Diabetes Association's 68th Scientific Sessions; June 6-10, 2008; San Francisco, CA. Abstract 2107-PO.
18. Jacobsen LV, Hindsberger C, Robson R, Zdravkovic M. Pharmacokinetics of the long-acting human GLP-1 analogue liraglutide in subjects with renal impairment [abstract]. Diabetologia. 2007;50(suppl 1):S352. Abstract 0852.
19. Garber A, Henry R, Ratner R, et al; LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): A randomized, 52 week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373:473-481.
20. Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD). Diabetes Care. 2009 [Epub ahead of print].
21. Russell-Jones D, Vaag A, Schmitz O, et al. Significantly better glycemic control and weight reduction with liraglutide, a once-daily human GLP-1 analog, compared with insulin glargine: All as add-on to metformin and a sulphonylurea in type 2 diabetes [abstract]. Diabetes. 2008;57(suppl 1):P536.
22. Blonde L, Rosenstock J, Sesti G, et al. Liraglutide: Superior glycemic control vs exenatide when added to metformin and/or SU in type 2 diabetes [abstract]. Presented at: The 2008 CDA/CSEM Professional Conference and Annual Meeting; October 15-18, 2008; Montreal, Quebec. Abstract 107.
23. Capital Markets Day: Liraglutide. Report published by Novo Nordisk. September 2008.
24. The effect of liraglutide on body weight in obese subjects without diabetes: An extension to trial NN8022-1807. http://clinicaltrials.gov/ct2/show/ NCT00480909?term=liraglutide&rank=13. Clinicaltrials.gov website. Accessed April 15, 2009.
25. The effect of liraglutide compared to sitagliptin, both in combination with metformin on glycaemic control in subjects with type 2 diabetes mellitus. Clinicaltrials.govwebsite. http://www.clinicaltrials.gov/ct2/results?term= liraglutide+and+sitagliptin. Accessed April 13, 2009.
26. Vilsboll T, Zdravkovic M, Le-Thi T, et al. Liraglutide treatment, blood pressure, and biomarkers of cardiovascular risk in patients with type 2 diabetes: 14 weeks monotherapy study. Diabetes. 2006;55(suppl 1):A465.
27. Nauck MA, Duran S, Kim D, et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: A non-inferiority study. Diabetologia. 2007;50:1561-1562.
28. Feinglos MN, Saad MF, Pi-Sunyer FX, An B, Santiago O. Liraglutide Dose-Response Study Group. Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with type 2 diabetes. Diabet Med. 2005;22:1016-1023.
29. Malm-Erjefalt M, Brondsted L, Zdravkovic M. The effects of liraglutide on intragastric pH in healthy human subjects [abstract]. Presented at: The American Diabetes Association's 68th Scientific Sessions; June 6-10, 2008; San Francisco, CA. Abstract 2144-PO.
30. Jacobsen LV, Brondsted L, Vouis J, Zdravkovic M. A randomized, double-blind, cross-over trial investigating the effect of liraglutide on the absorption of an oral contraceptive drug [abstract]. Presented at: The American Diabetes Association's 68th Scientific Sessions; June 6-10, 2008; San Francisco, CA. Abstract 2047-PO.
31. Malm-Erjefalt M, Ekblom M, Brondsted L, Vouis J, Lennernas H, Zdravkovic M. A randomised, double-blind, cross-over trial investigating the effect of liraglutide on the absorption pharmacokinetics of concomitantly administered oral drugs in healthy subjects [abstract]. Presented at: The American Diabetes Association's 68th Scientific Sessions; June 6-10, 2008; San Francisco, CA. Abstract 434-P.
32. Kapitza C, Flint A, Hindsberger C, Zdravkovic M. The effect of the once-daily human GLP-1 analogue liraglutide on the pharmacokinetics of paracetamol [abstract]. Presented at: The American Diabetes Association's 68th Scientific Sessions; June 6-10, 2008; San Francisco, CA. Abstract 2145-PO.
33. Harder H, Nielsen L, Tu DT, Astrup A. The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabetes Care. 2004;27:1915-1921.
34. Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR; NN2211-1310 International Study Group. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): A 12-week, double-blind, randomized, controlled trial. Diabetes Care. 2004;27:1335-1342.
35. Nauck MA, Hompesch M, Filipczak R, Le TD, Zdravkovic M, Gumprecht J; NN2211-1499 Study Group. Five weeks of treatment with the GLP-1 analogue liraglutide improves glycemic control and lowers body weight in subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes. 2006;114:417-423.
36. Flint A, Nazzal K, Jagielski P, Segel S, Zdravkovic M. Influence of hepatic impairment on pharmacokinetics of the long-acting human GLP-1 analogue liraglutide [abstract]. Presented at: The American Diabetes Association's 67th Scientific Sessions; June 22-26, 2008; Chicago, IL. Abstract 0545-P. F